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ABSTRACT: 
Objectives: The aim was to conduct a meta-analysis of the randomized evidence to 
determine the relative merits of laparoscopic assisted (LADG) and open (ODG) distal 
gastrectomy for proven gastric cancer. 
 
Data sources and review methods: A search of the Medline, Embase, Science 
Citation Index, Current Contents and PubMed databases identified all randomized 
clinical trials (RCTs) that compared LADG and OGD and were published in the 
English language between January 1990 and the end of June 2007. The meta-analysis 
was prepared in accordance with the Quality of Reporting of Meta-analyses 
(QUOROM) statement. The eight outcome variables analysed were operating time, 
blood loss, retrieval of lymph nodes, oral intake, hospital stay, postoperative 
complications, tumour recurrence and mortality. Random effects meta-analyses were 
performed using odds ratios (OR) and weighted mean differences (WMD). 
 
Results: Four trials were considered suitable for meta-analysis. A total of 81 patients 
underwent LADG and 80 had ODG. For only one of the eight outcomes, the summary 
point estimates favoured LADG over ODG; there was a significant reduction of 
104.26 mls in the intra-operative blood loss for LADG (WMD, -104.26, 95% 
confidence interval (c.i.) -189.01 to -19.51; P = 0.0159). There was however a 83.08 
minutes longer duration of operating time for the LADG group compared with the 
ODG group (WMD 83.08, 95% c.i. 40.53 – 125.64; P = 0.0001) and significant 
reduction in lymph nodes harvesting of 4.34 lymph nodes in the LADG group (WMD 
-4.3, 95% c.i. -6.66 to -2.02; P = 0.0002). Other outcome variables such as time to 
commencement of oral intake (WMD -0.97, 95% c.i. -2.47 to 0.54 ; P = 0.2068); 
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duration of hospital stay (WMD -3.32, 95% c.i. -7.69 to 1.05; P = 0.1365); rate of 
complications (OR 0.66, 95% c.i. 0.27 to 1.60; P = 0.3530); mortality rates (OR 0.94, 
95% c.i. 0.21 – 4.19; P = 0.9363) and tumour recurrence (OR 1.08 (95% c.i. 0.42 – 
2.79; P = 0.8806) were not found to be statistically significant for either group.  
However, for commencement of oral intake, duration of hospital stay and 
complication rate, the trend was in favour of LADG.  
 
Conclusion: LADG was associated with a significantly reduced rate of intra-
operative blood loss, at the expense of significantly longer operating time and 
significantly reduced lymph node retrieval compared to its open counterpart. 
Mortality and tumour recurrence rates were similar between the two groups. 
Furthermore, time to commencement of oral intake, post procedural discharge from 
hospital and the perioperative complication rate although not significantly different 
between the two groups did suggest a positive trend toward LADG. Based on this 
meta-analysis, the authors cannot recommend the routine use of LADG over ODG for 
the treatment of distal gastric cancer. However, significant limitations exist in the 
interpretation of this data due to the limited number of published randomised control 
trials, the small sample sizes to date, and the limited duration of follow up. Further 
large multicentre randomised controlled trials are required to delineate significantly 
quantifiable differences between the two groups. 
 
 4
INTRODUCTION: 
Minimal access gastrointestinal surgery for gastric cancer in the form of laparoscopic 
distal gastrectomy was introduced 13 years ago by the Japanese surgeons1. However, 
its wider acceptance as an alternative to an open approach remains a contentious 
issue. There could be a number of reasons for such a slow acceptance which include 
the complexity of the procedure especially the subsequent reconstruction of the 
alimentary tract and oncological adequacy and safety in terms of R0 resection, lymph 
nodes harvesting and tumour recurrence at the trocar sites2. The other factor which 
may have slowed its progress is the extent of the associated lymph node dissection, an 
issue which is viewed differently by the Japanese and Western Surgeons3-8.  However, 
recent years have also seen a tremendous amount of advancement in the development 
of laparoscopic instruments which, coupled with increasing experience in the 
performance of complex laparoscopic gastrointestinal procedures, have led to the 
expansion of minimal access surgery for both benign and malignant gastric 
procedures.  
 
Our aim therefore was to conduct an appraisal, based on a meta-analysis of pooled 
data from 4 available randomized clinical trials9-12, to compare the laparoscopic and 
open methods of distal gastrectomy for gastric cancer with a view to providing some 
clarity on a number of issues considered to be controversial. This meta-analysis was 
prepared in accordance with the Quality of Reporting of Meta-analyses (QUOROM) 
statement13. 
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MATERIAL AND METHODS: 
Randomized clinical trials of any size that compared LADG with ODG for gastric 
cancer, and were published in full in peer-reviewed journals in the English language 
between January 1990 and the end of June 2000, were included. Unpublished studies 
and abstracts presented at national and international meetings were excluded. Trials 
were identified by conducting a comprehensive search of Medline, Embase, Science 
Citation Index, Current Contents and PubMed databases, using medical subject 
headings (MESH) ‘gastrectomy’, ‘comparative study’, ‘prospective studies’, 
‘randomized controlled trials’, ‘random allocation’ and ‘clinical trial’. A manual 
search of the bibliographies of relevant papers was also carried out to identify trials 
for possible inclusion. Data extraction and critical appraisal were carried out by three 
authors independently (BM, RB, MAM). Eight outcome variables were considered 
most suitable for analysis: operating time, blood loss, retrieval of lymph nodes, oral 
intake, hospital stay, postoperative complications, tumour recurrence and mortality 
rate. The quality of the randomized clinical trials was assessed using Jadad’s scoring 
system14 by the two authors (BM, RB) (Table 1). 
 
STATISTICAL ANALYSIS: 
Meta-analyses were performed using odds ratios (ORs) for binary and weighted mean 
differences (WMDs) for continuous outcome measures. The slightly amended 
estimator15 of OR is used to avoid the computation of reciprocal of zeros among 
observed values in the calculation of the original OR. Random effects models by 
using the weighted method approach were used to combine the data and statistical 
heterogeneity was assessed using the χ2 test16. A sensitivity analysis was carried out to 
assess the impact of study quality on the results, by excluding poor-quality studies 
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(Jadad score 1). Funnel plots (Fig 9) were constructed to detect publication bias in 
meta-analysis by plotting both size and precision (1/standard error) against the 
treatment effect (MDs/LORs) for each outcome variables16-18. Sixteen funnel plots are 
plotted for 8 outcome variables. Eight of them are size based funnel plots while 
another 8 are standard error based funnel plots. For this meta-analysis, the number of 
points in the funnel plots (the number of studies) are few i.e. 4 in each plot, therefore 
the detection of bias is limited17,19. The funnel plots were produced to show (a) that 
the conclusion about the shape or visual interpretation may alter by plotting treatment 
effects against precision error instead of the sample size16,18 and (b) the limitation in 
the use of funnel plots to detect publication bias when the number of studies are small. 
All estimates were obtained using a computer program written by R, an open source 
software (copyright © 1998–2007 by Kurt Hornik)20. All plots were obtained using a 
computer program written by means of S-PLUS 2000® (Insightful Corporation, 
Seattle, USA).    
 
RESULTS: 
A total of 4 randomized prospective clinical trials that included 161 distal 
gastrectomies (LADG 81, ODG 80) were considered suitable for meta-analysis. In 
general, the quality of the studies was poor on critical appraisal (mean quality score 
2.7 of 5) (Table 1). This was because the method of randomization was not defined in 
every study, it was not possible to blind study participants and investigators for these 
procedures, and a description of withdrawals and drop-outs was not always provided. 
This is not an uncommon feature amongst the surgical RCTs, and has been observed 
in many reviews and meta-analyses of surgical trials21-23. The pooled data (OR and 
WMD) for the eight outcomes are summarized in Table 2 and Figs 1–8. As 
 7
statistically significant heterogeneity was evident for the majority of outcome 
variables, random effects models were used to combine the data24. A total of 81 
patients underwent LADG and 80 had ODG. For only one of the eight outcome 
variables, the summary point estimates favoured LADG over ODG; there was a 
significant reduction of 104.26 mls in the intra-operative blood loss for LADG (WMD 
-104.26, 95% confidence interval (c.i.) -189.01 to -19.51; P = 0.0159). There was 
however a 83.08 minutes longer duration of operating time for the LADG group 
compared with the ODG group (WMD 83.08, 95% c.i. 40.53 – 125.64; P = 0.0001) 
and significant reduction in lymph nodes harvesting of 4.34 lymph nodes in the 
LADG group (WMD -4.3, 95% c.i. -6.66 to -2.02; P = 0.0002). Other outcome 
variables such as time to commencement of oral intake (WMD -0.97, 95% c.i. -2.47 to 
0.54 ; P = 2068); duration of hospital stay for LADG (WMD -3.32, 95% c.i. -7.69 to 
1.05; P = 0.1365); rate of complications (OR 0.66, 95% c.i. 0.27 to 1.60; P = 0.3530); 
mortality rates (OR 0.94, 95% c.i. 0.21 – 4.19; P = 0.9363) and tumour recurrence 
(OR 1.08, 95% c.i. 0.42 – 2.79; P = 0.8806) were not found to be statistically 
significant for either group.  However, for commencement of oral intake, duration of 
hospital stay and complication rate, the trend was in favour of LADG.  
  
DISCUSSIONS: 
The proponents of LADG argue that the procedure is superior to ODG because it is 
associated with less postoperative pain, reduced peri-operative blood loss, quicker 
return to gastrointestinal function, faster hospital discharge, an earlier return to work 
and unrestricted physical activity, and a better cosmetic result2 . The opponents, 
however, argue that there is a higher incidence of major intraoperative and 
postoperative complications because of the complexity of the procedure and absence 
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of tactile sensation, substantially greater costs, much longer anaesthetic and operating 
time, decreased numbers of lymph nodes harvesting essential for oncological 
adequacy, insufficient surgical resection margins and potential for cancer 
reimplantation at trocar sites2. Furthermore, long-term consequences are unknown. 
This controversy has encouraged a number of investigators9-12 to initiate randomized 
clinical trials in an attempt to address some of these issues. However all these 
comparative trials have recruited a limited number of patients to date and the long 
term follow-up is not available. To clarify some of these issues, we undertook the 
present meta-analysis, concentrating on eight treatment variables that could be 
analysed objectively. To our knowledge no meta-analyses or a systematic review on 
this subject has been undertaken or published.  
 
All the trials reported the duration of operation. The meta-analysis revealed 
statistically significant longer operating time for LADG than for ODG (Fig. 1). This 
has important implications for both patients and the healthcare providers. Longer 
operations expose patients to a protracted anaesthesia, which may increase the 
morbidity and even mortality rates especially in older patients with co-morbidities. 
The vast majority of patients in these four RCTs were in their late 50s or early 60s 
with concomitant co-morbidies including cardio-pulmonary issues, diabetes etc. 
Longer operating and anaesthesia times also increase the direct cost of the procedure. 
Even with experience, the operating time for LADG has remained substantially longer 
to date. Without exception, all the RCTs (Fig 1) have clearly shown longer operating 
time for LADG by the authors who are considered experienced upper GI and 
laparoscopic surgeons. The longer operating time for LADG may in part reflect an 
early learning curve, as this is a relatively new procedure. Furthermore, the operating 
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time for LADG also includes the time for setting up laparoscopic equipments. Other 
reasons include lack of tactile sensation, the complexity of procedure, the post-
resectional reconstruction of gastrointestinal tract and the extent of lymphadenectomy 
performed at least by the Japenese surgeons.  
 
Regarding the intra-operative blood loss, three out of four RCTs9,10,12 (Fig 2) have 
shown decreased blood loss for LADG compared to ODG. This translates into 
decreased transfusion requirement in the peri-operative period with its inherent risk of 
acute or late adverse effects such as acute lung injury, volume overload, hypothermia, 
graft versus host disease and immunomodulatory effects to name but a few. The last 
side effect is especially important in cancer patients as a number of studies and a 
meta-analysis has suggested a significant deleterious transfusion effect in all cancer 
sites, except for breast25,26. Furthermore, the blood transfusion economics has not 
been addressed in any of these studies. A multicentre study on blood transfusion cost 
performed in 199127 revealed the average hospital cost per unit transfused was $155 
which would be far higher now. It is therefore evident from this meta-analysis that 
LADG have biological, immunological and economical benefits for the patient and 
the health care system by reducing peri-operative transfusion needs.   
 
Concerning oncological adequacy for lymph node harvesting, the number of lymph 
nodes retrieved laparoscopically in all these RCTs were sufficient (Fig 3) where the 
global standard for adequate staging is concerned, emphasizing the oncological 
capability of laparoscopic gastric procedures2. In fact, in none of the RCTs the lymph 
nodes retrieval for the two procedures has shown any significant statistical difference. 
However, when the results were pooled together (Fig 3), there was a statistically 
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significant reduction in lymph node harvesting for LADG compared to ODG which 
may translate into an overall survival disadvantage for patients having LADG. As the 
long term results for the majority of these trials have not been published, this 
assumption is difficult to corroborate.  
 
The debate concerning the merits and risks of extended lymph node clearance during 
gastrectomy for cancer remains a contentious issue. A number of authors still feel that 
clinical benefit from extended lymphadenectomy for gastric cancer has no proven 
benefit and may even be counterproductive. A large retrospective study from 
Finland28 analysing 223 patients (D1=114, D2=109) undergoing curative gastrectomy 
found the surgical complication to be statistically higher for D2 cohort (33% vs 
16.8%) although hospital mortality was similar between the two groups. Furthermore 
D2 lymphadenectomy was associated with a longer postoperative hospital stay, 
operating time, blood loss and increased need for blood transfusions. A large Japanese 
multicentre RCT29 consisting of 523 patients once again showed higher morbidity for 
the extended (D2) surgery compared to the D1 group (28.1% vs 20.9%) for curative 
gastric cancer. This difference however did not reach statistical significance. 
Nonetheless, the authors felt that extended (D2) surgery can be added without 
increasing major surgical complications in this setting. Yet another RCT from The 
Netherlands30 analysing 711 patients (D1=380, D2=331) has shown a significantly 
higher morbidity and mortality for the D2 group (25% vs 43% and 4% vs 10% 
respectively) without affecting the five year survival rate. The Cochrane Review31 has 
shown no survival benefit for extended lymph node dissection but showed increased 
postoperative mortality and morbidity. Miura et al32 performed a critical reappraisal 
from the viewpoint of lymph node retrieval and found that laparoscopic D2 resection 
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harvested sufficient numbers of nodes for adequate TNM classification in 86% of 
cases. However, a significantly greater number of lymph nodes were harvested by the 
open method. They concluded that the extent of lymphadenectomy achieved by 
current laparoscopic procedures approaches the global standard for accurate staging, 
although performing extended resection laparoscopically as recommended in Japan 
remains a challenge and is a time consuming process. The authors therefore suggested 
that laparoscopic gastrectomy is only justified for more advanced disease under the 
setting of clinical trials.  
 
Except for Kitano et al9, all the other RCTs10-12 showed early resumption of oral 
intake by the patients undergoing LADG (Fig 4). The pooled data showed a positive 
trend for LADG, however this did not reach statistical significance. Three out of the 
four trials9,11,12 which reported on postoperative recovery of gastrointestinal function 
(passage of first flatus) showed that patients in all these trials have a quicker return of 
their gastrointestinal function and in two of these trials, this difference was 
significant9,12. Quicker return of gastrointestinal function has a direct impact on early 
resumption of diet which is shown in these trials and this allows early discharge with 
economical benefits.  
 
Three out of four RCTs10-12 showed a trend towards earlier discharge from hospital 
after LADG (Fig 5). Pooling the data from these trials failed to show any difference in 
the discharge data for these two procedures although the trend favoured LADG (Table 
2). Early-discharge is associated with lower medical direct, non-medical direct, and 
indirect costs than conventional inpatient care. Cost savings per patient therefore can 
be significant. Furthermore, early discharge also has a positive effect on pressure on 
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hospital beds which in certain countries have decreased due to restructuring of health 
services and have a direct impact on elective admissions. It is entirely possible that 
larger RCTs may show that LADG indeed have a clear cut advantage over ODG in 
terms of hospital discharge. We eagerly await any such data. 
 
None of the present trials have provided comparative data on patients returned to 
normal activity following LADG and ODG. However, all the RCTs have shown that 
the frequency, dose and duration of analgesia requirement for LADG have been lower 
in the peri-operative period. This is most likely due to the absence of a large 
abdominal incision in LADG. Two of the four RCTs9,10 have shown significantly 
early ambulation in their patients undergoing LADG. All these findings translate into 
a quicker return of biological functions, early hospital discharge and quicker return to 
normal activities. Obviously an objective assessment would be ideal using one of the 
health profile questionnaires which measures physical, mental, or emotional problems 
or limitations in patients’ daily life in the immediate and late peri-operative periods. 
This may have a major repercussion both for the employers and society in general.  
 
As far as the complication rate of these two procedures is concerned, the present 
analysis showed a higher incidence of peri-operative complications after ODG, (Fig. 
6). However this did not reach statistical significance when compared to LADG. 
Because laparoscopic surgery avoids a large abdominal incision, this decreases the 
incidence of postoperative pain which in turn decreases the incidence of atelectasis, 
hypoventilation, pneumonia and coronary ischaemia. A number of RCTs and 
observational studies have shown that laparoscopic procedures are associated with 
less suppression of FVC and FEV1 compared to their open counterpart33-36. In all the 
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RCTs of LADG vs ODG, the authors have observed more cardiorespiratory 
complications following ODG compared to LADG. Also the incidence of wound 
infection is higher for the open cohort because of the larger incision size. It is well 
known that reducing the number of complications should produce significant savings 
with an equal or better health outcome. The laparoscopic gastric procedure in this 
meta-analysis has shown 34% reduction in the relative odds of complications which 
although not statistically significant certainly translate into better outcome for the 
patient and the health care system.  
 
Lastly, there was no significant difference in mortality rate (Fig 7) and tumour 
recurrence (Fig 8) between the two procedures. There could be a number of 
explanations for such parity. First of all the number of patients in all these RCTs are 
relatively small which may have masked the true difference in mortality rate. 
Secondly, the follow-up data is short and therefore the real difference in the tumour 
recurrence may not be apparent presently. Once the data from these trials is matured, 
one will be able to get a clearer picture on these outcomes variables.  
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CONCLUSIONS: 
The present meta-analysis included a total of 161 distal gastrectomies for cancer, the 
largest body of information so far available for the comparison of LADG and ODG in 
the English language literature. Laparoscopic gastrectomy was associated with 
significantly decreased blood loss and positive trends towards fewer postoperative 
complications, quicker commencement of oral intake, earlier hospital discharge and 
early mobilization with decreased requirement for analgesia, but at the expense of a 
significantly longer operating time and fewer lymph nodes retrieval. Based on these 
data the authors feel the clear cut benefits of LADG over ODG are rather limited and 
its widespread adaptation cannot be recommended. However, significant limitations 
exist in the interpretation of this data due to the limited number of published 
randomised control trials, the small sample sizes to date, and the limited duration of 
follow up. Further large multicentre randomised controlled trials are required to 
delineate significantly quantifiable differences between the two groups. Nonetheless, 
it may be concluded that LADG is a safe and effective alternative to ODG and is 
justifiable under the setting of clinical trials. 
 
 1
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Table 1: Jadad’s score  
Authors Year Country Randomisation Blinding Withdrawal Total Jadad’s Score  
       
Kitano et al9  2002 Japan 2  0 1 3 
Lee et al11 2005 Korea 2  0 1 3 
Hayashi et al12 2005 Japan 2  0 1 3 
Huscher et al10 2005 Italy 1  0 1 2 
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Table 2 Summary of pooled data comparing LADG and ODG 
 
Variables Pooled OR or WMD Test for overall effect Test for heterogeneity 
  Z  p  2χ  p  
Duration of operating time (min) 83.08 (40.53, 125.64) ‡ 3.83 0.0001 91.93 <0.0001 
Intraoperative blood loss (mls) -104.26 (-189.01, -19.51) ‡ -2.41 0.0159 13.56 0.0037 
Lymph nodes harvesting -4.34 (-6.66, -2.02) ‡ -3.66 0.0002 1.68 0.6421 
Time to commencement of oral intake (day) -0.97 (-2.47, 0.54) ‡ -1.26 0.2068 36.90 <0.0001 
Duration of hospital stay (day) -3.32 (-7.69, 1.05) ‡ -1.49 0.1365 33.54 <0.0001 
Complication rate 0.66 (0.27, 1.60) * -0.93 0.3530 4.87 0.1819 
Mortality rate 0.94 (0.21, 4.19) * -0.08 0.9363 0.78 0.8547 
Tumour recurrence 1.08 (0.42, 2.79) * 0.15 0.8806 0.01 0.9998 
Values in parentheses are 95 percent confidence intervals. *OR odds ratio; ‡ WMD weighted mean difference. 
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From the test of heterogeneity, 4 variables (duration of operating time (min), intraoperative blood loss (mls), time to commencement of oral 
intake (day) and duration of hospital stay (day) are found rejecting the null hypothesis that is all true treatment effects for 4 studies (references) 
are the same (statistically significant with p-value <0.004.  
 
The random effect method is applied to all variables to find the pooled point estimate and confidence interval of the mean effect.  
 
Later the overall effect test is used to test whether the pooled estimate is different from zero (i.e. whether the difference due to LADG and ODG 
is statistically significant). The test of overall effect shows statistically significant longer operating time for LADG than ODG (p-value =0.0001) 
but statistically significant more blood loss and more lymph nodes for ODG than LADG (p-value <0.05). The data fails to reject the null 
hypothesis that LADG and ODG are not different for time to commencement of oral intake, duration of hospital stay, complication rate, 
mortality rate and tumour recurrence. 
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Mean of duration of operation in minutes (standard deviation) 
 
Pt LADG Pt ODG MD (95% c.i.) Authors weight 
 
-50 0 50 100 150 200 250
 
83.08 ( 40.53 , 125.64 )
favours L favours O  
Kitano et al 14 227 (7) 14 171 (13) 56 (48.27, 63.73) 0.28 
Lee et al 24 319 (16.2) 23 190.4 (39.1) 128.6 (111.36, 145.84) 0.27 
Hayashi et al 14 378 (97) 14 235 (71) 143 (80.03, 205.97) 0.17 
Huscher et al 30 196 (21) 29 168 (29) 28 (15.04, 40.96) 0.28 
Pooled 81 268.37 (1817.68) 80 186.69 (1643.58) 83.08 (40.53, 125.64)* 1
   
Fig. 1 Values in left panel are mean (standard deviation), mean difference (95% c.i.), weighted mean difference (95% c.i.) and weight. In the graph, squares indicate point 
estimates of treatment effect (mean difference, i.e. mean for LADG group of patients – mean for ODG group of patients) with the size of the squares representing the weight 
attribute to each study. The horizontal lines represent 95% confidence interval for means differences. The pooled estimate of operating time (minutes) is the weighted mean 
difference, obtained by combining all means differences using the inverse weighted method and is represented by the diamond and the size of the diamond depicts the ninety-
five percent confidence interval. Values to the left of the vertical line at zero favour LADG. 
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Mean of blood loss in mls (standard deviation) 
 
 
-300 -200 -100 0 100 200
 
-104.26 ( -189.01 , -19.51 )
favours L favours O
 
Pt LADG Pt ODG MD (95% c.i.) Authors weight 
Kitano et al 14 117 (30) 14 258 (53) -141 (-172.90, -109.10) 0.35 
Lee et al 24 336 (180) 23 294 (156) 42 (-54.35, 138.35) 0.25 
Hayashi et al 14 327 (245) 14 489 (301) -162 (-365.30, 41.30) 0.12 
Huscher et al 30 229 (144) 29 391 (136) -162 (-233.45, -90.55) 0.29 
Pooled 81 258.04 (27449.42) 80 357.10 (29864.09) -104.26 (-189.01, -19.51)* 1 
   
Fig. 2 Values in left panel are mean (standard deviation), mean difference (95% c.i.), weighted mean difference (95% c.i.) and weight. In the graph, squares indicate point 
estimates of treatment effect (mean difference, i.e. mean for LADG group of patients – mean for ODG group of patients) with the size of the squares representing the weight 
attribute to each study. The horizontal lines represent 95% confidence interval for means differences. The pooled estimate of blood loss (mls) is the weighted mean 
difference, obtained by combining all means differences using the inverse weighted method and is represented by the diamond and the size of the diamond depicts the ninety-
five percent confidence interval. Values to the left of the vertical line at zero favour LADG.
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Mean of lymph nodes harvested (standard deviation) 
 
Pt LADG Pt ODG MD (95% c.i.) Authors weight 
 
-15 -10 -5 0 5 10 15
 
-4.34 ( -6.66 , -2.02 )
favours O favours L  
Kitano et al 14 20.2(3.6) 14 24.9 (3.5) -4.7(-7.33, -2.07) 0.78
Lee et al 24 31.8(13.5) 23 38.1(15.9) -6.3(-14.75,2.15) 0.08
Hayashi et al 14 28(14) 14 27(10) 1(-8.01,10.01) 0.07
Huscher et al 30 30(14.9) 29 33.4(17.4) -3.4(-11.68,4.88) 0.08
Pooled 81 28.51(171.11) 80 32.14 (203.93) -4.3(-6.66, -2.02)* 1
   
 
Fig 3 Values in left panel are mean (standard deviation), mean difference (95% c.i.), weighted mean difference (95% c.i.) and weight. In the graph, squares indicate point 
estimates of treatment effect (mean difference, i.e. mean for LADG group of patients – mean for ODG group of patients) with the size of the squares representing the weight 
attribute to each study. The horizontal lines represent 95% confidence interval for means differences. The pooled estimate of lymph nodes harvested (units) is the weighted 
mean difference, obtained by combining all means differences using the inverse weighted method and is represented by the diamond and the size of the diamond depicts the 
ninety-five percent confidence interval. Values to the left of the vertical line at zero favour ODG. 
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Mean of oral intake in days (standard deviation) 
 
Pt LADG Pt ODG MD (95% c.i.) Authors weight 
 
-3 -2 -1 0 1 2 3
 
-0.97 ( -2.47 , 0.54 )
favours L favours O  
Kitano et al 14 5.3 (1.5) 14 4.5(0.3) 0.80(-0.001,1.60) 0.26
Lee et al 24 5.3(1.4) 23 5.7(2.8) -0.40(-1.67, 0.87) 0.23
Hayashi et al 14 3.5(0.8) 14 5.4(1.2) -1.90(-2.66, -1.14) 0.26
Huscher et al 30 5.1(0.5) 29 7.4(2.0) -2.30(-3.05, -1.55) 0.26
Pooled 81 4.92(1.15) 80 6.05(4.00) -0.97(-2.47,0.54)* 1
   
Fig. 4 Values in left panel are mean (standard deviation), mean difference (95% c.i.), weighted mean difference (95% c.i.) and weight. In the graph, squares indicate point 
estimates of treatment effect (mean difference, i.e. mean for LADG group of patients – mean for ODG group of patients) with the size of the squares representing the weight 
attribute to each study. The horizontal lines represent 95% confidence interval for means differences. The pooled estimate of time to commencement of oral intake (days) is 
the weighted mean difference, obtained by combining all means differences using the inverse weighted method and is represented by the diamond and the size of the diamond 
depicts the ninety-five percent confidence interval. Values to the left of the vertical line at zero favour LADG.
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Mean of duration of hospital stay in days (standard deviation) 
 
Pt LADG Pt ODG MD (95% c.i.) Authors weight 
 
-15 -10 -5 0 5 10
 
-3.32 ( -7.69 , 1.05 )
favours L favours O  
Kitano et al 14 17.6 (2.6) 14 16(0.4) 1.6(0.22, 2.98) 0.29
Lee et al 24 11.2(4.2) 23 17.3(15.5) -6.1(-12.65,0.45) 0.18
Hayashi et al 14 12(2) 14 18(6) -6(-9.31,-2.69) 0.25
Huscher et al 30 10.3(3.6) 29 14.5(4.6) -4.2(-6.32, -2.09) 0.28
Pooled 81 12.1(11.81) 80 16.18(83.53) -3.32(-7.69, 1.05)* 1
   
 
Fig. 5 Values in left panel are mean (standard deviation), mean difference (95% c.i.), weighted mean difference (95% c.i.) and weight. In the graph, squares indicate point 
estimates of treatment effect (mean difference, i.e. mean for LADG group of patients – mean for ODG group of patients) with the size of the squares representing the weight 
attribute to each study. The horizontal lines represent 95% confidence interval for means differences. The pooled estimate of duration of hospital stay (days) is the weighted 
mean difference, obtained by combining all means differences using the inverse weighted method and is represented by the diamond and the size of the diamond depicts the 
ninety-five percent confidence interval. Values to the left of the vertical line at zero favour LADG. 
. 
 
 24 
Odds ratio for complications 
 
LADG ODG Authors OR (95% c.i.) weight 
 
0.05 0.10 0.50 1.00 5.00 10.00
 
0.66 ( 0.27 , 1.6 )
favours LADG Odds ratio favours ODG  
Kitano et al 2 of 14 4 of 14 0.47(0.08,2.69) 0.19
Lee et al 3 of 24 10 of 23 0.21(0.05,0.84) 0.25
Hayashi et al 8 of 14 6 of 14 1.71(0.40,7.25) 0.24
Huscher et al 8 of 30 8 of 29 0.96(0.31,2.93) 0.32
Pooled 21 of 81 28 of 80 0.66(0.27,1.60) 1
  
Fig. 6 In the graph, squares indicate point estimates of treatment effect (odds ratio for LADG over ODG groups) with the size of the squares representing the weight attribute 
to each study. The horizontal lines represent 95% confidence interval for odds ratio. The pooled estimate for complication rate (is the pooled odds ratio obtained by 
combining all odds ratio of the four studies using the inverse weighted method) and is represented by the diamond and the size of the diamond depicts the ninety-five percent 
confidence interval. Values to the left of the vertical line at one favour LADG. 
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Odds ratio for mortality 
 
LADG ODG Authors OR (95% c.i.) weight 
 
0.05 0.10 0.50 1.00 5.00 10.00
 
0.94 ( 0.21 , 4.19 )
favours LADG Odds ratio favours ODG  
Kitano et al 0 of 14 0 of 14 1(0.02,53.89) 0.14
Lee et al 0 of 24 0 of 23 0.96(0.02,50.35) 0.14
Hayashi et al 1 of 14 0 of 14 3.22(0.12,86.10) 0.21
Huscher et al 1 of 30 2 of 29 0.56(0.07,4.52) 0.51
Pooled 2 of 81 2 of 80 0.94(0.21,4.19) 1
  
Fig. 7 In the graph, squares indicate point estimates of treatment effect (odds ratio for LADG over ODG groups) with the size of the squares representing the weight attribute 
to each study. The horizontal lines represent 95% confidence interval for odds ratio. The pooled estimate for mortality rate (is the pooled odds ratio obtained by combining all 
odds ratio of the four studies using the inverse weighted method) and is represented by the diamond and the size of the diamond depicts the ninety-five percent confidence 
interval. Values to the left of the vertical line at one favour LADG. 
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27 
Fig. 8 In the graph, squares indicate point estimates of treatment effect (odds ratio for LADG over ODG groups) with the size of the squares representing the weight attribute 
to each study. The horizontal lines represent 95% confidence interval for odds ratio. The pooled estimate for tumour recurrence (is the pooled odds ratio obtained by 
combining all odds ratio of the four studies using the inverse weighted method) and is represented by the diamond and the size of the diamond depicts the ninety-five percent 
confidence interval. Values to the left of the vertical line at one favour LADG. 
           
0.05 0.10 0.50 1.00 5.00 10.00
 
1.08 ( 0.42 , 2.79 )
favours LADG Odds ratio favours ODG  
 
Odds ratio for tumour recurrence 
 
 
Authors LADG ODG OR (95% c.i.) weight 
Kitano et al 0 of 14 0 of 14 1.00(0.02,53.89) 0.06
Lee et al 0 of 24 0 of 23 0.96(0.02,50.35) 0.06
Hayashi et al 0 of 14 0 of 14 1.00(0.02,53.90) 0.06
Huscher et al 11 of 30 10 of 29 1.10(0.38,3.12) 0.83
Pooled 11 of 81 10 of 80 1.08(0.42,2.79) 1
  
 
  
Fig 9: Funnel plots for every treatment from the studies included in meta-analysis. Precision = 
1/standard error. 
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